Cullinan Therapeutics CGEM
Valuation
Multiples measured against the stock's own five-year history
Around its usual level · 53rd percentile, 5-year average -2.7x
Near the top of its 5-year range · 87th percentile, 5-year average 1.4x
#3388 of 5329 stocks by PB (1 = cheapest)
Above its usual level · 61st percentile, 5-year average 35.0x
#4832 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.37 | – | 1.44 | 87% (pricier than usual) | #3388 of 5329 (1 = cheapest) |
| PE | -3.33 | -3.37 | -2.73 | 53% (pricier than usual) | – |
| PS | 35.23 | 27.15 | 34.98 | 61% (pricier than usual) | #4832 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on CGEM.
Sign in to join the discussion.